What to Ask Before Starting Targeted Therapy in Pune

A molecular result alone does not tell you whether a drug will help, how long it may work, or what it will cost to manage. By asking about the specimen, evidence, treatment goal, monitoring, safety, and next steps, you can evaluate a proposed plan with greater clarity before the first dose.

Which test proves that I have a treatable target?

A treatable target is proved by the tumour’s pathology and biomarker profile, not by the organ where the cancer began. A biopsy supplies tissue; histopathology identifies the cancer type and appearance. The biomarker method then tests a specific protein, gene change, fusion, or genomic pattern.

Before targeted cancer treatment in Pune, ask:

• Which biomarker is being tested, and is the result predictive of treatment benefit or only prognostic?
• Is this assay a clinically validated companion diagnostic for the proposed drug?
• Did the laboratory receive enough viable tumour, and was the tumour percentage sufficient?
• Could decalcification of a bone sample have damaged DNA or RNA?
• Where was the test performed, what quality accreditation and limitations does the laboratory report, and how long will results take?
• Who will interpret a variant of uncertain significance, and is an outside pathology review needed?

A negative liquid biopsy does not always exclude a target: small tumour burden or low tumour shedding can leave little circulating tumour DNA. If that result would change treatment, ask whether adequate tissue should be tested or re-tested during your targeted therapy consultation in Pune.

How do I read the molecular pathology report and judge the evidence?

A pathology report describes what the tumour looks like under the microscope. A molecular report identifies selected genetic or protein changes, using methods such as immunohistochemistry, fluorescence in situ hybridisation, or next-generation sequencing. Read both before treating a reported target as a treatment recommendation.

1. Identify the exact finding: mutation, fusion, amplification, protein expression, or genomic signature. An actionable mutation or fusion supports a drug choice only when the cancer type, biomarker, and supporting evidence match.

2. Separate certainty from possibility. A variant of unknown significance is an uncertain finding, not proof that a drug will work. Ask who interpreted it and whether an outside pathology review or molecular review is needed.

3. Check whether the result is tumour-only or germline. A germline finding may be inherited, so ask about genetic counselling and implications for relatives; it is not the same as a tumour-only alteration.

4. Ask what the biomarker predicts. It may predict treatment benefit, describe prognosis, or have no approved treatment at all. Ask whether the proposed use is regulatory-approved for this cancer and biomarker, guideline-supported, available only through a clinical trial, or off-label. These categories are not interchangeable.

The key question in a precision oncology in Pune consultation is not simply whether a target was found. Ask for the expected benefit in your tumour type, including response probability, duration, survival evidence, and quality-of-life trade-offs, and ask where the test was performed and what its limitations are.

What is the treatment trying to achieve, and why this option?

The goal determines whether a targeted drug belongs in your plan: cure, tumour shrinkage before surgery or radiation, recurrence prevention after initial treatment, control of advanced disease, or symptom relief. Ask whether the biomarker predicts benefit from this drug or merely describes disease behaviour; a biologically plausible alteration is not proof of effectiveness.

Before agreeing to targeted cancer treatment in Pune, ask:

• Which cancer types and stages have evidence for this approach?
• What response probability, usual benefit duration, survival evidence, and quality-of-life trade-offs apply to my stage, symptoms, organ function, previous treatment, and goals?
• Is this use regulatory-approved, guideline-supported, available only in a clinical trial, or off-label?
• What do you recommend if the target is absent or the evidence is too weak?

A precision oncology in Pune consultation should connect the report to these alternatives, not rely on the mutation’s name alone. Ask how long treatment continues and what outcome would make the doctor stop or change it.

What exactly will I take, and how will safety, cost, and follow-up be managed?

Before signing consent or taking the first dose, record the exact drug name, molecular target, route, dose, schedule, planned duration, and whether it is a tablet, capsule, injection, or intravenous infusion. Ask which scan or response test will be used, and when it will occur.

• Confirm dates for complete blood counts, liver and kidney tests, blood-pressure checks, heart assessments, and other drug-specific monitoring.
• Ask which result triggers a dose interruption, dose reduction, treatment change, or hospital admission.
• Get same-day contact instructions for fever, severe diarrhoea, rash, breathlessness, jaundice, bleeding, chest pain, or an infusion reaction. Ask which symptoms require emergency care.
• Review every prescription, over-the-counter medicine, supplement, and herbal product. CYP enzymes, gastric-acid suppression, food, and other medicines can change oral drug levels.
• Discuss pregnancy, contraception, breastfeeding, fertility preservation, and sperm or egg storage before treatment.

Your estimate should include biomarker testing, scans, laboratory monitoring, supportive medicines, admissions, emergencies, interruptions, and drug availability—not only the drug price. A targeted therapy consultation in Pune can use this checklist when comparing care plans from a targeted therapy doctor in Pune, including Dr. Pratik Patil - Best Oncologist in Pune.

Related services

What happens if the tumour progresses or the treatment stops working?

Progression means a defined change, such as tumour growth on the planned scan, a new lesion, or clinical worsening—not simply a bad day. Ask for the review interval, response-assessment test, blood-count and organ-function checks, symptom contact route, and the decision points for dose interruption, dose reduction, or treatment change.

Ask these questions before treatment begins:

• Which symptoms require an earlier review, and whom do I call during evenings or weekends?
• Who will review my scans and molecular findings, and how quickly will I receive the results?
• Could resistance reflect a secondary mutation, a bypass pathway, or changed tumour histology?
• Would a repeat tissue biopsy or liquid biopsy identify the cause and open a useful treatment option?
• If liquid biopsy is negative, could low tumour shedding or a small disease burden have hidden the target? Should adequate tissue be tested?

Repeat testing is not routine for every patient. Recommend it when the disease changes, resistance is suspected, the original sample was inadequate, or a new result could alter treatment.

For targeted cancer treatment in Pune, ask what happens if the medicine is unavailable or unaffordable, including scan, testing, emergency, and supportive-care costs. A precision oncology in Pune plan should not end with the first prescription.

Frequently asked questions

• Which test proves that I have a treatable target?

  A biopsy provides tumour tissue, histopathology identifies the cancer, and biomarker testing checks for a specific protein, gene change, fusion, or genomic pattern. Ask which result makes the target actionable and whether the test used was immunohistochemistry, fluorescence in situ hybridisation, polymerase chain reaction, or next-generation sequencing.

• How do I read a molecular pathology report?

  Check the specimen tested, biomarker method, exact variant or protein result, percentage or intensity when reported, laboratory interpretation, and evidence level. Ask whether the result is validated for your cancer type and whether a tissue-quality or tumour-cell limitation affects confidence.

• What should I ask about the treatment plan?

  Ask what the treatment aims to achieve, why it fits your target, whether the goal is tumour shrinkage, disease control, symptom relief, or reducing recurrence risk, and what alternatives exist.

• How will safety, cost, and follow-up be managed?

  Confirm the medicine name, dose, schedule, route, monitoring tests, warning symptoms, drug interactions, refill process, total expected cost, and review dates. Ask who to contact outside appointments.

• What happens if the tumour progresses or treatment stops working?

  Ask how progression will be confirmed, which scan or biopsy would be used, whether repeat biomarker testing could identify resistance, and which next options include another targeted drug, chemotherapy, immunotherapy, a clinical trial, or supportive care.

Related services